Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
33.23
-0.43 (-1.28%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Celldex Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Celldex Therapeutics stock have an average target of 46.6, with a low estimate of 34 and a high estimate of 68. The average target predicts an increase of 40.23% from the current stock price of 33.23.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Celldex Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 5 | 5 | 5 |
| Buy | 4 | 4 | 4 | 3 | 3 | 4 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Sell → Buy Upgrades $24 → $45 | Sell → Buy | Upgrades | $24 → $45 | +35.42% | Apr 20, 2026 |
| Goldman Sachs | Goldman Sachs | Hold Maintains $30 → $34 | Hold | Maintains | $30 → $34 | +2.32% | Mar 2, 2026 |
| Stifel | Stifel | Strong Buy Reiterates $58 → $68 | Strong Buy | Reiterates | $58 → $68 | +104.63% | Feb 26, 2026 |
| Barclays | Barclays | Sell Maintains $21 → $24 | Sell | Maintains | $21 → $24 | -27.78% | Dec 17, 2025 |
| Barclays | Barclays | Sell Maintains $25 → $21 | Sell | Maintains | $25 → $21 | -36.80% | Nov 11, 2025 |
Financial Forecast
Revenue This Year
3.27M
from 1.55M
Increased by 111.39%
Revenue Next Year
10.97M
from 3.27M
Increased by 235.85%
EPS This Year
-4.90
from -3.90
EPS Next Year
-4.90
from -4.90
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 12.6M | 36.6M | ||||||
| Avg | 3.3M | 11.0M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 715.5% | 1,021.9% | ||||||
| Avg | 111.4% | 235.9% | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.86 | -3.86 | ||||||
| Avg | -4.90 | -4.90 | ||||||
| Low | -5.17 | -5.79 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.